[Relationship between insulin resistance and bone metabolism].
It is well known that insulin plays an important role in bone metabolism. In addition, resent reports have demonstrated that adipocytokine and peroxisome proliferator-activated receptors (PPARs) , which are involved in insulin resistance, dramatically affect bone metabolism. In particular, Food and Drug Administration of the United States Department of Health and Human Service (FDA) noted that rosiglitazone and pioglitazone, PPAR gamma agonists, have an increased risk of bone fractures. This review focuses on the relationship between molecules involved in insulin resistance and bone metabolism.
Hamada
Yasuhiro
Y
Division of Nephrology, Kobe University School of Medicine/Department of Nutrition, Kobe University Hospital.
D054392:Adipokines / Q000502:physiology; D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D050260:Carbohydrate Metabolism; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007328:Insulin / Q000502:physiology*; D007333:Insulin Resistance; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000502:physiology; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects
D054392:Adipokines; D007004:Hypoglycemic Agents; D007328:Insulin; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone